Centessa Pharmaceuticals plc

Contributing Author

Recent Articles by Centessa Pharmaceuticals plc

Dec-11	Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications CNTA GlobeNewswire
Nov-11	Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares CNTA GlobeNewswire
Nov-11	Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares CNTA GlobeNewswire
Nov-07	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences CNTA GlobeNewswire
Nov-05	Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program CNTA GlobeNewswire
Sep-03	Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference CNTA GlobeNewswire
Aug-12	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 CNTA GlobeNewswire
Jun-16	Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year CNTA GlobeNewswire
May-19	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences CNTA GlobeNewswire
May-14	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025 CNTA GlobeNewswire